Cullinan Therapeutics, Inc. (CGEM) Cash Flow Statement

The OCF/NI ratio consistently below 1.0 indicates that net losses are partially non-cash, primarily due to stock-based compensation. This suggests that cash burn is somewhat less severe than net income implies, but the persistent gap warrants monitoring as SBC dilutes shareholders without immediate cash outflow.

The FCF trajectory shows a general increase in quarterly burn, particularly in 2025Q2, likely tied to pivotal trial initiation. With no revenue, FCF margins are undefined, and the trend suggests escalating cash needs as programs advance, reinforcing the urgency for external capital.

The negligible CapEx underscores a reliance on outsourced manufacturing and CROs, typical for clinical-stage biotech. This implies that cash burn is driven by R&D and operating expenses rather than capital intensity, but it also means the company lacks tangible asset backing, increasing reliance on pipeline success.

The variability in working capital suggests timing effects from clinical trial payments and vendor terms. Positive changes in recent quarters may indicate efficient payables management or prepayments, but the small magnitudes relative to burn imply limited liquidity buffer from working capital optimization.

The absence of capital returns is consistent with a pre-revenue company conserving cash for clinical development. This deployment strategy prioritizes pipeline advancement, but the lack of shareholder returns and the high burn rate heighten the need for future financing, likely dilutive.

The cumulative divergence between net income and operating cash flow is largely attributable to non-cash charges like stock-based compensation. This suggests that while cash burn is substantial, the economic cost to shareholders is higher when including dilution, and the company's cash runway is shorter than net losses alone might imply.